[Form 4] PULSE BIOSCIENCES, INC. Insider Trading Activity

Rhea-AI Filing Summary

PULSE BIOSCIENCES, INC. Chief Executive Officer Paul A. Laviollette purchased 15,000 shares of the company’s common stock in an open-market transaction. The shares were bought at a price of $19.69 per share and are held directly, bringing his direct ownership to 15,000 shares.

According to the disclosure, the shares were acquired through the company’s at-the-market equity offering program under an Equity Distribution Agreement with TD Securities (USA) LLC. The purchases occurred during an open trading window and in line with the company’s Insider Trading Policy and applicable securities laws.

Insights

Equity analyst

CEO makes a direct open-market share purchase via the company’s ATM program.

Chief Executive Officer Paul A. Laviollette acquired 15,000 shares of PULSE BIOSCIENCES, INC. common stock at $19.69 per share. The transaction is an open-market purchase executed through the company’s at-the-market equity offering program and results in direct ownership of 15,000 shares.

The filing notes that the purchases occurred during an open trading window under the company’s Insider Trading Policy and in accordance with securities laws. There are no derivative positions reported, and no sales or tax-related dispositions in this filing. Overall, this represents a straightforward net-buy transaction by the CEO.

Insider Trade Summary

Net Buyer: 15,000 shares ($295,350)

Net Buy 1 txn

Insider LAVIOLETTE PAUL A

Role Chief Executive Officer

Bought 15,000 shs ($295K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	15,000	$19.69	$295K

Holdings After Transaction: Common Stock — 15,000 shares (Direct, null)

Footnotes (1)

1. The shares reported herein were acquired through the Company's at-the-market equity offering program established pursuant to that certain Equity Distribution Agreement, dated February 19, 2026, by and between the Company and TD Securities (USA) LLC, as sales agent. The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws. The shares reported herein were acquired in a negotiated through the Company's at-the-market equity offering program at the prevailing market bid price or better at the time of sale.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAVIOLETTE PAUL A

(Last) (First) (Middle)

C/O PULSE BIOSCIENCES, INC.

601 BRICKELL KEY DRIVE, SUITE 1080

(Street)

MIAMI FLORIDA 33131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2026		P(1)		15,000	A	$19.69(2)	15,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares reported herein were acquired through the Company's at-the-market equity offering program established pursuant to that certain Equity Distribution Agreement, dated February 19, 2026, by and between the Company and TD Securities (USA) LLC, as sales agent. The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws.

2. The shares reported herein were acquired in a negotiated through the Company's at-the-market equity offering program at the prevailing market bid price or better at the time of sale.

	/s/ Kenneth B. Stratton, as Attorney-in-Fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)